Xeris Pharmaceuticals Inc (XERS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xeris Pharmaceuticals Inc (XERS) has a cash flow conversion efficiency ratio of -0.849x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($8.26 Million) by net assets ($-9.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Xeris Pharmaceuticals Inc (XERS) total market value for the company's overall valuation and market capitalisation.
Xeris Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Xeris Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Xeris Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xeris Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore Xeris Pharmaceuticals Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anhui Shenjian New Materials Co Ltd
SHE:002361
|
0.019x |
|
Wolverine World Wide Inc
NYSE:WWW
|
-0.192x |
|
Arlo Technologies
NYSE:ARLO
|
0.072x |
|
Central Plaza Hotel Public Company Limited
BK:CENTEL-R
|
0.057x |
|
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
|
-0.108x |
|
Varroc Engineering Limited
NSE:VARROC
|
0.199x |
|
VA Tech Wabag Limited
NSE:WABAG
|
-0.021x |
|
Orezone Gold Corporation
AU:ORE
|
0.302x |
Annual Cash Flow Conversion Efficiency for Xeris Pharmaceuticals Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Xeris Pharmaceuticals Inc from 2016 to 2025. View Xeris Pharmaceuticals Inc (XERS) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $13.69 Million | $28.63 Million | 2.091x | +67.46% |
| 2024-12-31 | $-29.61 Million | $-36.98 Million | 1.249x | -81.99% |
| 2023-12-31 | $-6.78 Million | $-47.02 Million | 6.934x | +404.50% |
| 2022-12-31 | $45.19 Million | $-102.89 Million | -2.277x | -126.98% |
| 2021-12-31 | $95.23 Million | $-95.53 Million | -1.003x | +82.02% |
| 2020-12-31 | $14.44 Million | $-80.56 Million | -5.580x | +22.80% |
| 2019-12-31 | $14.44 Million | $-104.35 Million | -7.228x | -868.48% |
| 2018-12-31 | $75.41 Million | $-56.28 Million | -0.746x | -275.00% |
| 2017-12-31 | $-57.83 Million | $-24.66 Million | 0.426x | -15.34% |
| 2016-12-31 | $-31.93 Million | $-16.09 Million | 0.504x | -- |
About Xeris Pharmaceuticals Inc
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related … Read more